Prostate Cell News Volume 9.36 | Sep 21 2018

TOP STORY

Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression

HSD17B2 expression was reduced as prostate cancer progresses. 17βHSD2 decreased potent androgen production by converting testosterone or dihydrotestosterone to their upstream precursors. HSD17B2 overexpression suppressed androgen-induced cell proliferation and xenograft growth. [Clin Cancer Res] Abstract

(Ranked by impact factor of the journal)

Inositol Polyphosphate 4-Phosphatase Type II Regulation of Androgen Receptor Activity

Investigators showed that INPP4B regulated AR transcriptional activity and the oncogenic signaling pathways Akt and PKC. Analysis of gene expression in prostate cancer patient cohorts showed a positive correlation between INPP4B expression and both AR mRNA levels and AR transcriptional output. [Oncogene] Abstract

A Reciprocal Feedback between the PDZ Binding Kinase and Androgen Receptor Drives Prostate Cancer

Scientists identified PDZ binding kinase (PBK) as a novel androgen receptor (AR)-regulated protein that regulated full-length AR and AR variants activity in prostate cancer (PrCa). PBK inhibition decreased growth of PrCa cell lines and clinical specimen cultured ex vivo. [Oncogene] Full Article

Sertad1 Promotes Prostate Cancer Progression through Binding Androgen Receptor Ligand Binding Domain

Researchers demonstrated that DHT inhibited SERTA domain-containing protein 1 (Sertad1) protein degradation in prostate cancer cell lines and that Sertad1 knockdown inhibited the proliferation of prostate cancer cells in vitro. [Int J Cancer] Abstract

SPOP Suppresses Prostate Cancer through Regulation of CYCLIN E1 Stability

The authors identified CYCLIN E1, as a novel substrate for SPOP. SPOP/CUL3/RBX1 complex regulated CYCLIN E1 stability through poly-ubiquitination. CYCLIN E1 expression rescued proliferation, migration, and tumor formation of prostate cancer cell suppressed by SPOP. [Cell Death Dis] Full Article

The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells

Remodeling of the collagenous extracellular matrix was associated with prostate cancer (PC) growth and invasion in the aged microenvironment. Moreover, the collagen matrix extracted from aged mice enhanced the invasiveness and proliferation of PC cells in vitro. [Mol Cancer Res] Abstract | Full Article

Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

Investigators demonstrated that C-X-C chemokine receptor type 7 (CXCR7), a seven-transmembrane G-protein-coupled chemokine receptor, is an androgen reecptor (AR)-repressed gene and is upregulated after androgen deprivation therapy. Macrophage migration inhibitory factor (MIF) was identified as a ligand for CXCR7, which induced expression of cell cycle genes through activating the AKT signaling pathway. [Mol Cancer Res] Abstract

Restoration of Tumor-Growth Suppression In Vivo via Systemic Nanoparticle-Mediated Delivery of PTEN mRNA

Researchers showed that phosphatase and tensin homologue deleted on chromosome 10 (PTEN) mRNA could be reintroduced into PTEN-null prostate cancer cells in vitro and in vivo via its encapsulation in polymer-lipid hybrid nanoparticles coated with a polyethylene glycol shell. The nanoparticles were stable in serum, elicited low toxicity and enabled high PTEN mRNA transfection in prostate cancer cells. [Nat Biomed Eng] Abstract | Press Release

PKM2 and HIF-1α Regulation in Prostate Cancer Cell Lines

Scientists demonstrated hypoxia-inducible factor 1α (HIF-1α) dependent up-regulation of pyruvate kinase M2 (PKM2) at the mRNA and protein levels in LNCaP cells. Additionally, PKM2 inhibition significantly reduced clonogenic survival in cell lines in a colony formation assay. [PLoS One] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

ADT with Antiandrogens in Prostate Cancer Induces Adverse Effect of Increasing Resistance, Neuroendocrine Differentiation and Tumor Metastasis

The authors summarize the unwanted androgen-deprivation-therapy (ADT)-induced side-effects and discuss multiple approaches to overcome these side-effects to better suppress prostate cancer at the castration resistant stage. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

NeoTract Announces Multiple Data Presentations from Studies of UroLift^® System Treatment for Enlarged Prostate

NeoTract announced that new clinical data from numerous studies of the UroLift^® System for patients with benign prostatic hyperplasia will be presented. [Press release from NeoTract, Inc. discussing research to be presented at the 36^th World Congress of Endourology (WCE) 2018 Annual Conference, Paris] Press Release

European Cancer Research Gets £30 Million Vote of Confidence

Cancer Research UK is partnering with two of Europe’s leading cancer research charities, Associazione Italiana per la Ricerca sul Cancro and Asociación Española Contra el Cáncer, to invest in six international collaborations, which are aimed at accelerating progress in translational research. [Cancer Research UK] Press Release

Rapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapa^™ Compound Targeting Early Stage Prostate Cancer

Rapamycin Holdings, Inc. has treated its first human patient with the company’s pharmaceutical formulation of its eRapa^™ compound. This first in human Phase Ib clinical trial of eRapa focuses on men with early stage prostate cancer. [Rapamycin Holdings, Inc. (Business Wire, Inc.)] Press Release

London Biotherapeutics Powerhouse Launched by Cancer Research UK

The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK. The new Cancer Research UK City of London Centre brings together world-leading researchers from UCL, King’s College London, Queen Mary University of London and the Francis Crick Institute. [Cancer Research UK] Press Release

Researchers Take Action to End Airlines’ Restrictions on Lab Animals

In a recently filed complaint to the US Department of Transportation, the National Association for Biomedical Research accuses four major airlines of illegally discriminating against customers wishing to fly animals destined for the lab. [The Scientist] Editorial

More and More Scientists Are Preregistering Their Studies. Should You?

Preregistration, in its simplest form, is a one-page document answering basic questions such as: What question will be studied? What is the hypothesis? What data will be collected, and how will they be analyzed? In its most rigorous form, a “registered report,” researchers write an entire paper, minus the results and discussion, and submit it for peer review at a journal, which decides whether to accept it in principle. [ScienceInsider] Editorial

Denied ‘Life-Extending Opportunities’: Black Patients Are Being Left Out of Clinical Trials amid Wave of New Cancer Therapies

Reflecting the reluctance of the FDA to force drug makers to enroll more minority patients, and the failure of most manufacturers to do so voluntarily, stark underrepresentation of African-Americans is widespread in clinical trials for cancer drugs, even when the type of cancer disproportionately affects them. [STAT News] Editorial

NSF Spells Out New Sexual Harassment Policy: Talk to Us

Starting next month, universities must tell the National Science Foundation (NSF) in Alexandria, Virginia, if any faculty members with NSF grants have been found guilty of sexual and other forms of harassment, or if they have suspended them for any reason. But NSF won’t pull its funding if institutions can assure the agency that another faculty member can take over the research project. [ScienceInsider] Editorial

NEW American Urological Association (AUA) Annual Meeting 2019
May 3-6, 2019
Chicago, Illinois, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellows – Prostate Cancer Research (Weill Cornell Medicine)

Postdoctoral Position – Genitourinary Cancers (Columbia University Medical Center)

Assistant Professor – Basic and Translational Cancer Research (Texas Tech University Health Sciences Center)

Assistant/Associate Faculty Position – Prostate Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Prostate Cancer Progression (Aarhus University)

Postdoctoral Position – Translational Cancer Research (University of California, Davis)

Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana)

Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic)

Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco)

Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.